Company updateOct 16, 2026OXB Appoints Joachim Kreuzburg as Independent Non-Executive DirectorOxford Biomedica plcCompany newsroom
Company updateSep 22, 2026Oxford Biomedica PLC Interim results for the six months ended 30 June 2026Oxford Biomedica plcCompany newsroom
Company updateAug 7, 2026Half Year Trading Update and Notice of ResultsOxford Biomedica plcCompany newsroom
Company updateJul 16, 2026OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy ProgrammeOxford Biomedica plcCompany newsroom
Company updateMay 8, 2026OXB to exhibit and present at the 30th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)Oxford Biomedica plcCompany newsroom
Company updateApr 13, 2026OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufactureOxford Biomedica plcCompany newsroom
Company updateMar 27, 2026OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership AwardsOxford Biomedica plcCompany newsroom
Company updateMar 26, 2026Preliminary results for the year ended 31 December 2025Oxford Biomedica plcCompany newsroom
Company updateMar 18, 2026OXB enters into licensing agreement with Viral Vector Manufacturing Facility (VVMF), providing access to its AAV and LV viral vector platformsOxford Biomedica plcCompany newsroom